Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vericel CorpVCEL · Entity 4481 | Chief Medical Officer | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vericel Corp
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,753 |
Last balance in matching sequence
After 2026-06-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 2 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 3 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 4 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 25,000 |
Reported balance
After 2026-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 25,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 20,000 |
Reported balance
After 2026-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 20,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.
F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-22-000613 · primary_01.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,604 Underlying: Common Stock · 10,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 6,738 | $41.46 | $279,370.96 |
DisclosureSEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,176 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 10,000 | $41.41 | $414,060.00 |
DisclosureSEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,914 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $10.95 | $109,500.00 |
DisclosureSEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $34.90 | $61,075.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 730 | $34.90 | $25,477.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,914 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 19, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 2,865 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,865 Underlying: Common Stock · 2,865 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 9,300 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:11 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 51,385 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,385 Underlying: Common Stock · 51,385 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,625 | $35.26 | $57,297.50 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 1,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 775 | $35.26 | $27,326.50 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,894 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 650 | $33.91 | $22,041.50 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 310 | $33.91 | $10,512.10 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,044 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 26,000 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,604 Underlying: Common Stock · 9,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,881 | $40.08 | $235,692.25 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,547 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $16.66 | $166,600.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 9,000 | $40.14 | $361,237.50 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,428 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 9,000 | $10.95 | $98,550.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,604 Underlying: Common Stock · 1,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,000 | $40.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,428 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,000 | $10.95 | $10,950.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:20 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 694 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001776 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,604 Underlying: Common Stock · 694 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:20 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 134 | $57.14 | $7,656.77 |
DisclosureSEC source: 0001593968-21-001776 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,319 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:20 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 694 | $10.95 | $7,599.30 |
DisclosureSEC source: 0001593968-21-001776 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 8,438 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,298 Underlying: Common Stock · 8,438 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,736 Underlying: Common Stock · 20,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,736 Underlying: Common Stock · 5,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 11,104 | $51.84 | $575,644.68 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,480 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 20,000 | $10.95 | $219,000.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 1,820 | $51.00 | $92,820.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,584 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 8,438 | $10.95 | $92,396.10 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $50.56 | $252,805.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,966 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $10.95 | $54,750.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 57,177 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,177 Underlying: Common Stock · 57,177 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 2,823 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 2,823 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,625 | $49.23 | $79,998.75 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 1,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 738 | $49.23 | $36,331.74 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,633 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 650 | $47.18 | $30,667.00 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC | Vericel Corp VCEL · Entity 4481 | Tax withholdingCommon Stock | 264 | $47.18 | $12,455.52 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,746 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 18,264 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,736 Underlying: Common Stock · 18,264 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 5,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.